Overview

* MoonLake reports Q3 net loss of $70.7 mln, EPS at -$1.10

* Company ends Q3 with $380.5 mln in cash, providing runway into H2 2027

* R&D expenses rise due to clinical trials, including sonelokimab trials

Outlook

* Company expects cash reserves to fund operations into H2 2027

* MoonLake plans Phase 3 PPP trial initiation in Q3 2026

Result Drivers

* Research and development expenses for the quarter ended September 30, 2025, were $60.6 million, compared to $49.8 million in the previous quarter

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$1.10

Q3 Net -$70.69

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for MoonLake Immunotherapeutics ( MLTX ) is $13.50, about 25% above its November 4 closing price of $10.13

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)